Skip to main content
Figure 2 | Diabetology & Metabolic Syndrome

Figure 2

From: Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers

Figure 2

Blood glucose profiles measured by CGM during glimepiride or repaglinide treatment (n = 8). Glimepiride was taken once a day in the morning, while repaglinide was taken three times a day before every meal. The blood glucose profiles on day 3 are shown for all patients. The effects of the meal with unrestricted calories consumed on day 1 and 2 were excluded from the analyses. Blight shade area shows mean ± SEM of serum glucose levels during glimepiride treatment. Dark shade area shows mean ± SEM of serum glucose levels during repaglinide treatment.

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us